Life Science Executive Awards
Monday 16 November 2026City Central at the HAC, London, UKDeal of the Year (>€500m)
This award recognises the teams and organisations who have executed a truly transformational and high value creating deal for both the company and the wider industry. The deal could be a licensing agreement, co-development or a creative alliance or partnership that unlocks significant value.
Criteria & Judging
Qualifying criteria:
- Total deal size (not milestone payments) must be greater than €500m
- The lead company must be a European Life Science company
- Open to private or public companies WITH pharma, commercial leaders or big tech
- Deal can be either a licensing deal involving a particular drug, project or group of drugs/projects
- A license, partnership or alliance between companies NOT M&A
- Deal to have completed in the period between 1 September 2025 and 1 August 2026
Judges will be paying particular attention to:
- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal
- Strength of partner / partnership and deal teams
- Potential game / industry changing implications within next 12-months
- Post-deal performance
